Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

DexCom’s Quarterly Earnings Preview: What You Need to Know

San Diego, California-based DexCom, Inc. (DXCM) is a medical technology company focused on continuous glucose monitoring (CGM) systems that enable real-time tracking of blood sugar levels for people with diabetes. Valued at $24.7 billion by market cap, its wearable devices, such as the G6 and next-generation G7, transmit continuous data to smartphones, helping users and healthcare providers manage glucose levels more effectively without frequent fingerstick testing.

The global leader in glucose biosensing is expected to post its fiscal first-quarter earnings for 2026 after the market closes on Thursday, Apr. 30. Ahead of the event, analysts expect DXCM to report a profit of $0.47 per share on a diluted basis, up 46.9% from $0.32 per share in the year-ago quarter. The company beat the consensus estimates in three of the last three quarters while missing the forecast on one occasion. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.